MOLECULAR PARTNERS AG (MOLN)
Molecular Partners AG engages in the development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. It also develops its products through its brand known as DARPins, which targets specific and potent monoclonal antibodies that offers potential to address existing limitations of antibody drugs. The company products include Abicipar, MP0250/MP0274 and Clinical Trials. The company was founded by Christian Zahnd, Patrick Amstutz, Patrik Forrer, Andreas Plückthun, and Michael Tobias Stumpp on November 22, 2004 and is headquartered in Schlieren, Switzerland.
Address
WAGISTRASSE 14
Z?RICH-SCHLIEREN, V8 8952
Founded
2004
Number of Employees
182
Website
http://www.molecularpartners.com
Insider Transactions
Filters
Keyboard Shortcuts: Show (a) | Close (Esc)